01Clinical context
What is the finding?
A suspicious pigmented lesion requires diagnostic assessment and exclusion of malignancy before any aesthetic procedure.
Melasma and Pigmentation Disorders · Medical Skin Care · Istanbul
Melasma and Pigmentation Disorders · Medical Skin Care · Istanbul
Melasma and Pigmentation Disorders
Melasma, solar lentigo, post-inflammatory hyperpigmentation, freckles and medicine- or hormone-related pigment change are not interchangeable diagnoses. A named care method, ingredient or infusion is not a diagnosis and does not establish personal suitability.
Online information cannot diagnose, select products or procedures, or promise an outcome. Final decisions require an in-person medical assessment.
Clinical Orientation
Finding · identity · evidence · safety
Four questions precede a personal plan.
The sequence prevents a category name from becoming an automatic treatment recommendation.
02Identity
What exactly is proposed?
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
03Evidence
What does the evidence support?
Melasma may relapse or flare; no product, peel or laser removes every pigmentation disorder.
04Safety
When should it stop?
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
Meaning and Boundary
Care is not a diagnosis
The category name does not determine the clinical decision.
Melasma, solar lentigo, post-inflammatory hyperpigmentation, freckles and medicine- or hormone-related pigment change are not interchangeable diagnoses.
What assessment may do
- Clarify a limited clinical aim
- Identify the exact method or product
- Compare risks and alternatives
- Set follow-up and stopping criteria
What must not be assumed
- Guarantee suitability or benefit
- Replace diagnosis or disease-directed treatment
- Create a public personal protocol
- Promise permanence, prevention or a general wellness effect
Pigment clearance and freedom from recurrence cannot be guaranteed.
Medical Suitability
Diagnosis and activity before care
Five checks come before selection.
History, examination, current treatment, contraindications and a proportionate alternative are reviewed together.
- 01
Clarify the problem
A suspicious pigmented lesion requires diagnostic assessment and exclusion of malignancy before any aesthetic procedure.
- 02
Review current treatment
Medicines, allergies, previous procedures or infusions and relevant reactions are considered.
- 03
Identify the exact option
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
- 04
Compare alternatives
Photoprotection, trigger review, diagnosis-led topical care, observation, dermatology assessment or no procedure
- 05
Plan follow-up
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
Care Path
Before · during · after
Safety depends on a complete, documented chain.
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
01Before
Confirm finding and skin state
A suspicious pigmented lesion requires diagnostic assessment and exclusion of malignancy before any aesthetic procedure.
- Review history and examination
- Check contraindications
- Keep alternatives open
02During
Control exposure and response
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
- Maintain traceability
- Monitor tolerance
- Stop when safety changes
03After
Separate expected response from harm
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
- Record observations
- Explain warning signs
- Provide a review route
No personal acid concentration, contact time, prescription medicine or home-treatment recipe is published.
Evidence and Limits
Method-, product- and indication-specific
Biology or popularity is not proof of clinical benefit.
Melasma may relapse or flare; no product, peel or laser removes every pigmentation disorder.
Keep the indication exact
Evidence in one diagnosis or deficiency does not establish a general effect.
Keep the intervention exact
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
Keep endpoints separate
Symptoms, photographs, laboratory values and patient-reported outcomes are not interchangeable.
Retain uncertainty
Pigment clearance and freedom from recurrence cannot be guaranteed.
Manufacturer information may identify a product and instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
Reason · option · review · exit
Personalisation means tighter decisions, not unlimited combinations.
A plan remains limited to a defined question and can conclude that no procedure or infusion is appropriate.
Name the reason
A suspicious pigmented lesion requires diagnostic assessment and exclusion of malignancy before any aesthetic procedure.
Name the option
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
Name the endpoint
Agree what would count as a meaningful and measurable change.
Name the exit
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
Course and Follow-Up
Expected response · complication · reassessment
Repetition is never automatic.
Tolerance and the agreed clinical endpoint are reviewed separately before any further intervention.
- 01Before
Baseline
Record the starting clinical context and intended endpoint.
- 02Same day
Immediate review
Observe tolerance and unexpected reactions.
- 03Later
Clinical review
Compare the relevant finding without automatic attribution.
- 04Decision
Continue, change or stop
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
Risks and Alternatives
Common, serious and delayed harm
Risk remains visible even when a treatment is described as supportive.
Irritation, burns, scarring, post-inflammatory hyperpigmentation, hypopigmentation and delayed diagnosis are recognised harms.
01Safety
Recognised harms
Irritation, burns, scarring, post-inflammatory hyperpigmentation, hypopigmentation and delayed diagnosis are recognised harms.
02Options
Alternatives
Photoprotection, trigger review, diagnosis-led topical care, observation, dermatology assessment or no procedure
03Action
Escalation
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Treatment is withheld when diagnosis or rationale, product identity, consent, safety controls or follow-up is inadequate. Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
Istanbul and Follow-Up
Assessment and review must travel together
International care needs a workable safety route.
Travel does not shorten observation or remove the need for local medical access.
01Before travel
Organise the question
History and existing records prepare discussion without confirming treatment.
02In Istanbul
Assess in person
A suspicious pigmented lesion requires diagnostic assessment and exclusion of malignancy before any aesthetic procedure.
03Treatment day
Keep exact records
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
04After return
Plan escalation
Stop and arrange assessment for a changing or bleeding lesion, severe irritation, blistering, delayed healing or marked colour change.
The Doctor Aslan Approach
Clinical question before treatment label
Selection follows diagnosis, identity, evidence and safety.
Doctor Aslan keeps the clinical question, exact intervention, realistic limits, alternatives and follow-up in the same decision.
Assess first
A suspicious pigmented lesion requires diagnostic assessment and exclusion of malignancy before any aesthetic procedure.
Verify identity
Photoprotection, trigger management, topical care, peels and device options have different roles and risks.
Limit the claim
Pigment clearance and freedom from recurrence cannot be guaranteed.
Accept no treatment
Observation or another established pathway may be the safer choice.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about Melasma and Pigmentation Disorders; no personal prescription or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Melasma and Pigmentation Disorders?+
Melasma and Pigmentation Disorders is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Melasma and Pigmentation Disorders?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the question · verify the option · compare alternatives